Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 310 of 6351
-
Single infusion may prevent chronic headaches after concussion
Disease control Not yet recruitingMost individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (…
Phase 3 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Poop pills may help revive immunotherapy in lung cancer patients
Disease control Not yet recruitingThis study aims to investigate the efficacy and safety of fecal microbiota transplantation (FMT) as a treatment for non-small cell lung cancer (NSCLC) patients whose disease has progressed after immune checkpoint inhibitor (ICI) therapy, and to establish the foundation for person…
Phase 2 • Sponsor: Se-Hoon Lee • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Hope for rett syndrome: new drug trial targets behavior and communication
Symptom relief Recruiting nowPrimary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and wom…
Phase 3 • Sponsor: Biomed Industries, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Triple-Drug cocktail aims to shrink head and neck tumors
Disease control Not yet recruitingThis is an open-label, randomized, prospective, multicenter phase III trial to evaluate the efficacy and safety of the combination therapy of cetuximab with either pembrolizumab or finotonlimab, alongside chemotherapy, as a first-line treatment, compared with pembrolizumab or fin…
Phase 3 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New targeted pill aims to keep KRAS lung cancer from returning after surgery
Disease control Recruiting nowThe main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-pos…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
Drug combo aims to shrink Hard-to-Treat anal cancer
Disease control Not yet recruitingThe goal of this clinical trial is to see the safety and efficacy of pembrolizumab and lenvatinib in patients with anal squamous cell cancer that cannot be removed through surgery or is spread to other organs. Eligible participants should have also received some form of standard …
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill aims to tame stubborn high blood pressure
Disease control Not yet recruitingThis is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average SBP in participants with uHTN. Consenting partici…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a new drug free PAH patients from daily pump therapy?
Disease control Not yet recruitingPulmonary arterial hypertension (PAH) is a rare lung disease that leads to elevated blood pressure in the lungs and strain on the right side of the heart. For many years, treatments for PAH have included drugs that target the prostacyclin pathway using intravenous, subcutaneous, …
Sponsor: University of Alberta • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Weekly pill cocktail aims to tame resistant blood cancers
Disease control Not yet recruitingThis is a single-center randomized phase 2 open-label clinical trial.
Phase 2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Brain zaps boost therapy for PTSD in troops with head injuries
Symptom relief Not yet recruitingIn this study, the investigators are evaluating whether transcranial direct current stimulation (tDCS), a brain stimulation technique, can be combined with Written Exposure Therapy (WET), a standard talk therapy for posttraumatic stress disorder (PTSD) to improve treatment respon…
Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Could gentle yoga and breathing ease Cancer's lingering toll?
Symptom relief Not yet recruitingThis clinical trial studies how well mind-body interventions work in improving quality of life (QOL), stress, and sleep quality among survivors of breast, prostate, endometrial, or colorectal cancer. For many cancer survivors, the experience of cancer extends well beyond the comp…
Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can a new pill slow kidney damage in IgA nephropathy?
Disease control Not yet recruitingThis is a multicenter, open-label study to evaluate the long-term safety and efficacy of FXS6837 capsules in primary IgAN patients. About 60 IgAN patients who had received and completed FXS6837-IIb-201 study treatment will be enrolled to take FXS6837 capsules orally according to …
Phase 2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new stent graft reinforce a weakened aorta and prevent rupture?
Disease control Recruiting nowThe objective of this clinical investigational study is to evaluate the safety and efficacy of the Ankura™ II AAA, AE Stent Graft System and the large-size Ankura™ II IE Stent Graft System (i.e., IE stent grafts with distal diameters of 24, 26, and 28 mm) for endovascular treatme…
Sponsor: Lifetech Scientific (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Ultrasound 'Memory' imaging may reveal hidden heart ischemia
Diagnosis Not yet recruitingMolecular imaging with myocardial contrast echocardiography (MCE) relies on the non-invasive detection of targeted microbubbles (MBs) or other acoustically active agents. The confinement of MBs to the vascular compartment makes them ideal for assessing acute inflammatory response…
Early phase 1 • Sponsor: University of Virginia • Aim: Diagnosis
Last updated Aug 22, 2026 00:00 UTC
-
Can a new pill help teens regrow hair lost to alopecia?
Disease control Not yet recruitingThis study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia areata (AA).
Phase 1 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Ancient remedy meets modern prebiotic: a new hope for Shift-Worker fatigue?
Symptom relief Not yet recruitingCertain classical formulas in traditional Chinese medicine and dietary prebiotics have demonstrated beneficial effects on various aspects of suboptimal health status in previous studies. This research aims to evaluate the effects of Bao Yuan Tang full-component extract combined w…
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Can a new pill tame childhood cancers that Won't quit?
Disease control Not yet recruitingThe primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
Phase 1 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could a daily glass of kefir soothe celiac gut troubles?
Symptom relief Not yet recruitingThis study will investigate whether regular consumption of kefir can reduce gastrointestinal symptoms and improve quality of life in adults with celiac disease who follow a strict gluten-free diet. The study will use a randomized cross-over design in which participants will consu…
Sponsor: University Maribor • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can a nerve stimulator outsmart a placebo for chronic pain?
Disease control Not yet recruitingThis study aims to determine whether ongoing BurstDR spinal cord stimulation (SCS) provides pain relief beyond sham stimulation in patients with chronic pain who are established responders to BurstDR therapy. Participants already implanted with an SCS system and experiencing sta…
Sponsor: Umeå University • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a new siRNA injection keep high triglycerides in check for the long haul?
Disease control Not yet recruitingThis is a Phase II multi-center, open-label extension (OLE) clinical trial of HRS-7249, a GalNAc-conjugated APOC3-targeted siRNA injection, enrolling two cohorts of participants. Cohort 1 includes subjects who completed parent study HRS-7249-201 within 24 weeks; Cohort 2 newly re…
Phase 2 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC